ANTHONY S. FAUCI, M.D.; BARTON F. HAYNES, M.D.; PAUL KATZ, M.D.; SHELDON M. WOLFF, M.D.
Eighty-five patients with Wegener's granulomatosis were studied for 21 years at the National Institutes of Health. Patients were treated with a protocol consisting of cyclophosphamide, 2 mg/kg body weight · d, together with prednisone, 1 mg/kg body weight · d, followed by conversion of the prednisone to an alternate-day regimen. Complete remissions were achieved in 79 of 85 patients (93%). The mean duration of remission for living patients was 48.2 (± 3.6) months. Twenty-three patients are off all therapy for a mean duration of 35.3 (± 6.3) months without therapy. This study provides a prospective experience with Wegener's granulomatosis and shows that long-term remissions can be induced and maintained in an extremely high number of patients by the combination of daily cyclophosphamide and alternate-day prednisone therapy.
Learn more about subscription options.
Register Now for a free account.
FAUCI AS, HAYNES BF, KATZ P, WOLFF SM. Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years. Ann Intern Med. 1983;98:76-85. doi: 10.7326/0003-4819-98-1-76
Download citation file:
Published: Ann Intern Med. 1983;98(1):76-85.
Autoimmune Kidney Disease, Interstitial Lung Disease, Nephrology, Pulmonary/Critical Care, Rheumatology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only